Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.32 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 3/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10267639 | 0.83 | USP30 (0.36) | PAX8HCRTR1HCRTR2USP30GRM5 | |
| SCHEMBL18768746 | 0.80 | PAX8 (0.42) | PAX8USP30GPR119 | |
| SCHEMBL31128417 | 0.80 | PAX8 (0.35) | PAX8BRD4GRM5CREBBP | |
| SCHEMBL852406 | 0.80 | PAX8 (0.42) | PAX8BRD4GRM5CREBBP | |
| SCHEMBL68085 | 0.80 | PAX8 (0.42) | PAX8BRD4GRM5CREBBPNCEH1 | |
| SCHEMBL2960607 | 0.79 | HCRTR1 (0.41) | HCRTR1HCRTR2USP30GRM5CTSK | |
| SCHEMBL23131099 | 0.79 | PAX8 (0.40) | PAX8BRD4CREBBP | |
| SCHEMBL14182011 | 0.79 | PAX8 (0.40) | PAX8BRD4CREBBPNCEH1 | |
| SCHEMBL21964982 | 0.78 | PAX8 (0.41) | PAX8BRD4CREBBPNCEH1 | |
| SCHEMBL14270683 | 0.78 | PAX8 (0.39) | PAX8BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-1424336-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | MIF, MORF4L1, FOXM1 | PAX8 3292/4885HCRTR1 3079/4885HCRTR2 3869/4885 |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | MIF, MORF4L1, FOXM1 | PAX8 3292/4885HCRTR1 3079/4885HCRTR2 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.